Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
作者:
Pablo Tebas,
William Powderly,
Sherry Claxton,
Donna Marin,
Woraphot Tantisiriwat,
Steven Teitelbaum,
Kevin Yarasheski,
期刊:
AIDS
(OVID Available online 2000)
卷期:
Volume 14,
issue 4
页码: 63-67
ISSN:0269-9370
年代: 2000
出版商: OVID
关键词: bone mineral metabolism;bone densitometry;osteoporosis;adiposity;aspartyl protease inhibitors;HIV infection
数据来源: OVID
摘要:
BackgroundThe use of highly active antiretroviral therapy (HAART) has been associated with multiple metabolic complications whose pathogenesis is poorly understood at the present time.MethodsWe performed a cross-sectional analysis of whole-body, lumbar spine (L1–L4) and proximal femur bone mineral density in 112 male subjects (HIV-infected patients on HAART that included a protease inhibitor, HIV-infected patients not receiving a protease inhibitor and healthy seronegative adults) using dual energy x-ray absorptiometry.ResultsMen receiving protease inhibitors had a higher incidence of osteopenia and osteoporosis according to World Health Organization definitions: relative risk = 2.19 (95% confidence interval 1.13–4.23) (P= 0.02). Subjects receiving protease inhibitors had greater central : appendicular adipose tissue ratios than the other two groups (P< 0.0001). There was no relationship between the central : appendicular fat ratio and the lumbar spine or proximal femur bone mineral densityt- orz- scores, suggesting that osteoporosis and body fat redistribution are independent side effects of HAART.ConclusionsOsteopenia and osteoporosis are unique metabolic complications associated with protease inhibitor-containing potent antiretroviral regimens, that appear to be independent of adipose tissue maldistribution.
点击下载:
PDF
(135KB)
返 回